脐带间充质干细胞移植治疗脊髓损伤的临床研究

目的:探讨脐带间充质干细胞移植治疗脊髓损伤的疗效及安全性。方法:40例脊髓损伤患者给予脐带间充质干细胞移植治疗,移植方法采用静脉输注联合腰穿鞘内注射的方法。术后随访1年余定期观察患者临床症状及各项指标的变化并进行综合分析。移植过程中为促进干细胞的生长和分化,根据患者病情及身体状况给予相应的康复功能锻炼。结果:与入院时比较,脐带间充质干细胞移植治疗3、6、12个月后,不完全性脊髓损伤患者针刺觉评分、轻触觉评分、运动评分均有明显改善(P<0.05或0.01),完全性脊髓损伤患者针刺觉评分、轻触觉评分、运动评分均无明显变化(P>0.05),两组残损分级均无明显改善(P>0.05)。移植后各项生化指标正常,未出现严重的并发症和明显的不良反应。结论:脐带间充质干细胞移植治疗脊髓损伤近期疗效明显,可以改善患者的临床症状,提高患者的生存质量,是一种值得借鉴的治疗方法。     

脐带间充质干细胞移植治疗50例缺血性下肢血管病的临床研究

目的:观察脐带间充质干细胞移植治疗缺血性下肢血管病的临床疗效并观察近期临床效果.方法:50例自愿接收脐带间充质干细胞移植患者中糖尿病足35例,动脉硬化闭塞症10例,血栓性闭塞性脉管炎5例.全部患者均给予静脉输注及局部种植脐带间充质干细胞.术后第7天至6个月定期观察各项指标的变化.结果:治疗1月后,47例(94％)疼痛有不同程度的缓解,46例(92％)患肢冷感明显缓解,45例(90％)患者行走距离延长.6月后30例糖尿病足患者溃疡或足部坏疽痊愈.结论:脐带间充质干细胞移植治疗缺血性下肢血管病是一种简便、安全、有效的治疗方法,其治疗的近期疗效显著,使很多患者免除截肢或降低截肢平面,明显改善患者生活质量.     

脐带间充质干细胞治疗粉碎性骨折1例并文献复习

目的:观察脐带间充质干细胞治疗粉碎性骨折的疗效和安全性。方法:将脐带间充质干细胞通静脉输注和局部多点注射到常规治疗效果欠佳自愿接受干细胞移植的1例粉碎性骨折患者,4次为一个疗程,每周间隔1次,每次治疗细胞总数(3~7)×107。术后1、3、6月定期观察患者临床症状及影像学的变化并进行动态观察。结果:脐带间充质干细胞治疗后一月,患者在不帮助的情况下可独立缓慢行走,复查X线提示骨折部位有新生骨形成;干细胞治疗后三月,复查X线提示骨折愈合较前好转;半年后,患者右下肢受力明显好转,可以独立自由行走,复查X线提示右下肢骨折部位有连续性骨痂形成,骨折部位愈合良好。结论:脐带间充质干细胞移植治疗粉碎性骨折是一种安全、有效的手段,可促进粉碎性骨折的愈合,改善其生活质量。     

脐带间充质干细胞辅助治疗糖皮质激素耐药的慢性移植物抗宿主病5例并文献复习

目的:探讨脐带间充质干细胞输注治疗糖皮质激素耐药的慢性移植物抗宿主病的疗效和安全性。方法:5例糖皮质激素耐药的慢性移植物抗宿主病患者在原有免疫抑制剂治疗基础上联合脐带间充质干细胞治疗,2~4次为1个疗程,每次间隔1周。对患者进行定期随访观察其治疗效果、移植相关死亡、输注相关不良事件和复发率。结果:5例患者接受脐带间充质干细胞输注后2例获得完全缓解(CR)、2例获得部分缓解(PR),1例患者死亡。2例CR患者分别在脐带间充质干细胞治疗368、452d后停用免疫抑制剂,随访1~1.5年慢性移植物抗宿主病无复发;2例PR患者在脐带间充质干细胞治疗84、96d后开始进入免疫抑制剂减量阶段,目前病情仍稳定并存活。1例患者死于原发病无复发性肺部严重感染。治疗过程中及治疗后未观察到与治疗有关的副作用。新鲜制备脐带间充质干细胞的细胞活力(92%~95%)高于液氮冻存37℃水浴复苏细胞活力(72%~76%)。结论:脐带间充质干细胞辅助治疗可以改善糖皮质激素耐药的慢性移植物抗宿主病的临床症状且不增加恶性血液病复发率,新鲜制备间充质干细胞活性高于液氮冻存复苏细胞。     

骨髓和脐带间充质干细胞联合移植治疗杜氏型肌营养不良1例并文献复习

目的:研究自体骨髓和脐带间充质干细胞联合移植治疗杜氏型肌营养不良(DMD)的疗效和安全性方法对经临床表现、血清酶学、肌电图、基因分析、肌肉活检、肌肉核磁共振成像(MRI)确诊的1例DMD患者采用自体骨髓和脐带间充质干细胞联合移植的方案进行治疗.术后第3、6、9、12个月定期观察患者临床症状及各项疗效指标的变化并结合国内外文献进行综合分析.结果随访12个月,该患者肌力提高,动作灵活.血清肌酸激酶和乳酸脱氢酶较前明显下降,活动能力评分和徒手肌力较前增加,肌电图运动单位电位波幅减低及时限缩短较前改善,肌肉MRI复查显示肌肉病变程度较前减轻、肌肉轮廓较前清晰.结论自体骨髓和脐带间充质干细胞联合移植是一种治疗DMD的有效治疗方法.     

脐带间充质干细胞辅助治疗难治性类风湿性关节炎的临床观察

目的:观察脐带间充质干细胞辅助治疗难治性类风湿性关节炎的疗效和安全性。方法:将细胞总数为(5~7)×107个脐带间充质干细胞通过静脉输注途径移植到自愿接受干细胞移植的2例难治性类风湿性关节炎患者体内,4次为1个疗程,每次间隔1周。治疗后随访1年定期观察患者临床症状及各项生化和免疫学指标的变化并进行综合分析。结果:脐带间充质干细胞辅助治疗后1月余,2例患者的临床症状明显改善,28个关节的疾病活动度评分(DAS-28)由3.6和4.0分别降低为2.2和2.6,血沉、C反应蛋白水平和类风湿因子抗体滴度也较治疗前明显降低。随访1年余未观察到与治疗有关的副作用,并且症状持续缓解无复发。结论:脐带间充质干细胞辅助治疗可缓解难治性类风湿性关节炎的临床症状,且未观察到与治疗有关的副作用,安全性好,值得临床进一步研究其远期疗效。     

鞘内注射脐带间充质干细胞治疗神经系统疾病的安全性和疗效研究（英文）

目的:探讨腰穿鞘内注射脐带间充质干细胞治疗神经系统疾病的安全性和疗效并且分析腰穿治疗过程中遇到的各种技术难题。方法:2008年12月至2011年5月88例伴有神经系统疾病的患者给予鞘内注射干细胞治疗,并且评价其在治疗过程中的技术难题,采用HAI评分系统对这些患者神经功能的恢复情况进行评估,定期观察患者的临床症状、生物学指标和影像学检查观察其治疗前后的变化。结果:88例患者中具有技术难题的患者有20例,主要表现为在鞘内注射脐带间充质干细胞的过程中需要行全麻补充、腰穿定位困难等,18例患者在治疗过程中出现副作用(头痛、低热、腰痛和下肢痛),但这些副作用在48小时内经过系统治疗后完全缓解。随访1年,50例患者神经功能得到一定改善,包括15例脊髓损伤患者、10例脑瘫患者、10例脑外伤后综合征患者、5例脑梗死后综合征患者、5例脊髓小脑共济失调患者和5例运动神经元病患者。结论:鞘内注射脐带间充质干细胞治疗神经系统疾病是安全和有效的,由于随访时间较短,有必要对这种治疗模式进行扩大的、双盲、安慰剂对照研究来进一步推广其临床应用。     

细胞移植治疗脑瘫的研究现状

小儿脑性瘫痪(简称脑瘫)是目前小儿时期最主要的神经运动功能伤残疾病,且终生存在。尽管有支持性医护,但是目前并没有效治疗的方法。近几年,许多实验室开展了利用干细胞移植治疗脑瘫动物模型的研究,并且报道说人脐血干细胞和间充质干细胞对于脑瘫是有治疗作用的。而神经干细胞也被用于移植治疗脑瘫动物模型,并被证明这些移植的神经干细胞能迁移至受损脑部并分化为神经元。本文就至今已发表的一些细胞移植治疗脑瘫的研究中所用到的细胞种类做一综述。     

细胞移植治疗脑瘫的研究现状

小儿脑性瘫痪（简称脑瘫）是目前小儿时期最主要的神经运动功能伤残疾病,且终生存在。尽管有支持性医护。但是目前并没有效治疗的方法。近几年,许多实验室开展了利用干细胞移植治疗脑瘫动物模型的研究,并且报道说人脐血干细胞和间充质干细胞对于脑瘫是有治疗作用的。而神经干细胞也被用于移植治疗脑瘫动物模型,并被证明这些移植的神经干细胞能迁移至受损脑部并分化为神经元。本文就至今已发表的一些细胞移植治疗脑瘫的研究中所用到的细胞种类做一综述。     

感觉统合训练结合常规康复训练对痉挛型脑瘫患儿平衡控制及运动功能的影响

目的:探讨感觉统合训练结合常规康复训练对痉挛型脑瘫患儿平衡控制及运动功能的影响。方法:选取2016年1月到2017年12月期间成都市妇女儿童中心医院康复科收治的痉挛型脑瘫患儿80例为研究对象,根据随机数字表法将80例患儿分为对照组(40例)和观察组(40例)。对照组患儿采用常规康复训练进行治疗,观察组患儿采用感觉统合训练结合常规康复训练进行治疗。比较两组脑瘫患儿的平衡控制功能、步态、粗大运动功能测试量表-88(GMFM-88)D区和E区的评分。结果:治疗3个月后两组患儿的Rivermead活动指数、Berg平衡量表得分均明显升高,且观察组患儿的Rivermead活动指数、Berg平衡量表得分高于对照组(P0.05)。治疗3个月后两组患儿的步行足长、步速明显增加,步宽明显减小(P0.05),且观察组患儿步行足长、步速大于对照组,步宽小于对照组(P0.05)。治疗3个月后两组患儿的GMFM-88 D区、GMFM-88 E区得分均分别明显升高(P0.05),且观察组患儿的GMFM-88 D区、GMFM-88 E区得分均分别高于对照组(P0.05)。结论:感觉统合训练结合常规康复训练可有效改善痉挛型脑瘫患儿的平衡控制功能、步态以及粗大运动功能。     

Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study

Background aimsPre-clinical evidence indicates that autologous bone marrow-derived mesenchymal stromal cell (BM-MSC) transplantation improves motor function in patients with central nervous system disorders.MethodsAfter providing informed consent, 52 patients with cerebral palsy (CP) who met the study criteria received BM-MSC transplantation. Gross motor function was assessed using the Gross Motor Function Measure (GMFM)-88 and GMFM-66 scales at baseline (before transplantation) and at 1 month, 6 months and 18 months post-transplantation. The participants completed the trial without visible side effects. The GMFM-66 percentile (motor growth curves) was used as the control index of motor function to exclude the interference of improvement with age.ResultsThe score domains A, B, C and D and the total GMFM-88 and GMFM-66 scores in participants increased at 1 month, 6 months and 18 months post-transplantation compared with the baseline value (P < 0.01). The scores of domain E also increased at 6 months and 18 months post-transplantation, although they were not significantly increased at 1 month post-transplantation. There were significant increases in the GMFM-66 score and the GMFM-66 percentile corresponding to patient age and Gross Motor Function Classification System level after cell transplantation.ConclusionsAutologous BM-MSC transplantation appears to be a feasible, safe and effective therapy for patients with CP. The treatment improved the development of children with CP with regard to motor function.     

Intensive rehabilitation in children with cerebral palsy: our view on the neuronal group selection theory

Cerebral palsy (CP) is one of the major forms of developmental disorders. There are different approaches and controversies in rehabilitation treatment. The Neuronal Group Selection theory could provide theoretical explanation for Stojcevi? Polovina rehabilitation method. The aim of the study was to evaluate long-term impact of intensive and continuously performed rehabilitation on the motor autonomy level children with CR Motor autonomy levels, defined according to the Gross Motor Function Classification System (GMFCS) and Gross Motor Function Measure (GMFM), were analyzed in 24 children with CP at the beginning of the study and at the last visit. During rehabilitation, GMFM scores increased above the expected value of initial GMFCS level in the majority of patients. Intensive rehabilitation had significant influence on motor improvement in children with CP.     

体外反搏治疗小儿急性脑外伤的临床应用分析

目的:探讨以体外反搏为主的综合康复治疗对脑外伤后偏瘫患儿运动功能和日常生活活动能力(ADL)的影响。方法:选择2015年7月至2017年7月我院神经外科收治的脑外伤后偏瘫患儿46例,将其随机分为对照组和治疗组。两组患者均采用常规的康复治疗和护理,对照组采取常规的物理治疗(PT治疗),治疗组患者给予以体外反搏为主的综合康复治疗。于治疗1、3个月后,评价和比较两组患者粗大运动能力(GMFM)评分、精细运动能力(FMFM)评分和日常生活能力(ADL)评分的变化。结果:治疗1、3个月后,两组患儿GMFM、FMFM评分均较治疗前明显增加(均P0.01),而治疗组治疗后GMFM、FMFM评分均明显高于对照组(均P0.01)。两组治疗一个月后ADL总有效率(显效率与有效率之和)分别为90.48%和76.19%,治疗三个月后分别为95.24%和85.71%,治疗组均显著高于对照组(均P0.05)。结论:以体外反搏为主的综合康复治疗有利于促进脑外伤后偏瘫患者ADL及部分运动功能的提高。     

脐带间充质干细胞治疗儿童重型免疫性血小板减少症的探索性研究

目的探讨脐带间充质干细胞（UC-MSC）输注治疗儿童重型免疫性血小板减少症（s ITP）的疗效及安全性。方法采用UC-MSC治疗儿童s ITP 3例。发病年龄为3个月至4岁,初治时血小板计数为（1-7）×10^9/L,3例均为s ITP,均出现严重出血,激素及免疫抑制剂无效或依赖。后给予2-3次（1次/周）静脉输注非血缘UC-MSC,输注细胞量为（1-2）×10^6/kg。输注后密切监测血象及肝肾功能等各项指标,观察疗效及不良反应。结果随访时间15-45个月,3例在输注细胞后渐显效：第1例在输注细胞后20 d血小板达到65×10^9/L,随访4个月,血小板均维持在1×10^11/L以上;第2例在输注细胞后41 d血小板达105×10^9/L,之后血小板一直维持正常;第3例在输注第2次细胞后血小板渐上升至2×10^11/L以上。输注过程中1例出现面色发红,1例出现血压升高,随访至今无明显不良反应。结论 UC-MSC对儿童重型ITP有一定的疗效,能提高儿童的生活质量;有必要扩大病例数,进一步研究UC-MSC治疗儿童ITP的疗效及机制。     

Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia—a single-center experience

Background aimsThe purpose of this study was to observe the outcome of co-transfusion of umbilical cord multipotent stromal cells (UC-MSC) and allogeneic hematopoietic stem cells in the treatment of heavily-transfused patients with severe aplastic anemia.MethodsOf the 22 patients, eight cases received haploidentical hematopoietic stem cells from granulocyte colony-stimulating factor–primed bone marrow and peripheral blood grafts; the other patients received granulocyte colony-stimulating factor–mobilized peripheral blood grafts from human leukocyte antigen–matched related (six cases) and unrelated donors (eight cases). MSCs were intravenously infused at a mean dose of 1.2 × 10⁶/ kg (range, 0.27–2.5 × 10⁶/kg). Fludarabine-based conditioning was conducted, and graft-versus-host disease prophylaxis containing cyclosporine A, methotrexate and mycophenolate mofetil with or without addition of anti-CD25 monoclonal antibody was performed. Hematopoietic engraftment, the occurrence of graft-versus-host disease (GVHD) and infections and overall survival were documented.ResultsAll patients had rapid engraftment; mean time for neutrophil and platelet recovery was 13.95 d and 20.27 d, respectively. No acute toxicity associated with UC-MSC transfusion was observed. Acute GVHD developed in seven cases (grade I–II), and none had development of chronic GVHD. Cytomegalovirus reactivation was observed in 11 cases. One patient died of pulmonary complication 6 months after transplantation. Twenty-one patients are currently alive, at a median follow-up of 15 months; they are transfusion-independent and reached full donor chimerism at the time of reporting.ConclusionsUC-MSC infusion might be an alternative option to promote hematopoietic engraftment and reduce the occurrence of GHVD in hematopoietic stem cell transplantation in the treatment of heavily transfused patients with severe aplastic anemia.     

Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells

Background aimsThe aims of this study were to observe the safety and effectiveness of umbilical cord mesenchymal stromal cells (UC-MSC) in the treatment of spinocerebellar ataxia (SCA) and multiple system atrophy-cerebellar type (MSA-C).MethodsFrom October 2009 to September 2010, 14 cases of SCA and 10 cases of MSA-C were given UC-MSC by weekly intrathecal injection, at a dose of 1 × 10⁶/kg four times as one course. All the patients received one course of treatment, except three patients who received two courses. The movement ability and quality of daily life were evaluated with the International Cooperative Ataxia Rating Scale (ICARS) and Activity of Daily Living Scale (ADL) and the scores compared with those before cell therapy. A follow-up of 6–15 months was carried out for all of the patients.ResultsThe results showed that the ICARS and ADL scores were significantly decreased 1 month after treatment (P < 0.01). The symptoms, including unstable walking and standing, slow movement, fine motor disorders of the upper limbs, writing difficulties and dysarthria, were greatly improved except for one patient, who had no response. The observed side-effects included dizziness (four patients), back pain (two cases) and headache (one case), which disappeared within 1–3 days. During the follow-up, 10 cases remained stable for half a year or longer, while 14 cases had regressed to the status prior to the treatment within 1–14 months (an average of 3 months).ConclusionsIntrathecal injection of UC-MSC is safe and can delay the progression of neurologic deficits for SCA and MSA-C patients.     

体外反搏治疗急性重症病毒性脑炎的临床疗效观察

目的:探讨以体外反搏为主的康复手段治疗急性重症病毒性脑炎的临床疗效。方法:选择2015年6月～2016年6月在我院康复科就诊的42例急性重症病毒性脑炎患儿,按照家长治疗意愿分成治疗组和对照组,每组21例。治疗一个月和三个月后,分析和比较两组的治疗前后粗大运动功能评定量表(GMFM)、平衡功能测量(Berg量表)和修订的Glasgow意识障碍评分量表评分的变化。结果:两组患儿平衡能力总有效率(显效率与有效率之和)分别为85.7%和57.1%,以及95.2%和66.7%,治疗组疗效明显优于对照组(P0.05)。两组治疗后1、3个月,GMFM、Glasgow意识障碍评分均较治疗前明显提高(P0.01),且治疗组治疗1、3个月后GMFM显著高于对照组(P0.01)。结论:以体外反搏为主的早期康复治疗有助于急性重症病毒性脑炎患者促醒及运动功能恢复。